Ovarian cancer can be difficult to diagnose early
A blood test that could detect ovarian cancer in its early stages is to be trialled in the UK in a new study.
Ovarian cancer symptoms can often be missed in the condition's early stages, which is why it's known as a "silent disease". It's the sixth most common cause of cancer death in females in the UK, with a 35 percent survival rate. Professor Sudha Sundar, from the University of Birmingham said early detection is vital as most cases are spotted when it's too late.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Manchester United loanee Amad scores screamer as Sunderland draw first blood in play-offManchester United loanee Amad Diallo scored a beautiful free-kick to help Sunderland beat Luton 2-1 in the first leg of their semi-final play-off. The United loanee lashed in a free-kick five minut…
Read more »
High blood pressure symptoms as 'silent killer' signs should never be ignoredIt's estimated that a third of people with high blood pressure are unaware that they have it, so it's important to get to know the signs.
Read more »
OPPO abandons custom chip design ambitionsPLUS: India gets blood from a drone; Toshiba sets a date; Australia floats metaverse standards
Read more »
Taylor Swift Shouts At Security Guard In Defence Of Fan At US Tour DateThe singer interrupted Bad Blood to try to defuse a situation in the crowd.
Read more »
The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial - Immunity & AgeingBackground Aging is associated with progressive declines in immune responses leading to increased risk of severe infection and diminished vaccination responses. Influenza (flu) is a leading killer of older adults despite availability of seasonal vaccines. Geroscience-guided interventions targeting biological aging could offer transformational approaches to reverse broad declines in immune responses with aging. Here, we evaluated effects of metformin, an FDA approved diabetes drug and candidate anti-aging drug, on flu vaccination responses and markers of immunological resilience in a pilot and feasibility double-blinded placebo-controlled study. Results Healthy older adults (non-diabetic/non-prediabetic, age: 74.4 ± 1.7 years) were randomized to metformin (n = 8, 1500 mg extended release/daily) or placebo (n = 7) treatment for 20 weeks and were vaccinated with high-dose flu vaccine after 10 weeks of treatment. Peripheral blood mononuclear cells (PBMCs), serum, and plasma were collected prior to treatment, immediately prior to vaccination, and 1, 5, and 10 weeks post vaccination. Increased serum antibody titers were observed post vaccination with no significant differences between groups. Metformin treatment led to trending increases in circulating T follicular helper cells post-vaccination. Furthermore, 20 weeks of metformin treatment reduced expression of exhaustion marker CD57 in circulating CD4 T cells. Conclusions Pre-vaccination metformin treatment improved some components of flu vaccine responses and reduced some markers of T cell exhaustion without serious adverse events in nondiabetic older adults. Thus, our findings highlight the potential utility of metformin to improve flu vaccine responses and reduce age-related immune exhaustion in older adults, providing improved immunological resilience in nondiabetic older adults.
Read more »